NYC Healthcare News



Intellect Neurosciences signs debt settlement agreement with CARBOGEN AMCIS AG

September 04, 2015

In the general population, the average score on RBANS tests is 100. Among liver patients in Randolph's study who had neurocognitive impairments, the average score was 74. This is lower than the average score of patients with early-stage Alzheimer's disease.

Prevalence of neurocognitive impairment was independent of age, gender, educational level or severity of the underlying disease.

The findings are a subset of a larger study to determine whether an experimental compound called AST-120 benefits liver patients who have neurocognitive impairments. AST-120 absorbs ammonia and other toxins. Patients have been randomly assigned to receive AST-120 or a placebo.

The study is funded by Ocera Therapeutics, which is developing compounds to treat liver diseases and other gastrointestinal disorders.

Source: Loyola University Health System